Table 2. Comparison of mpDECT between benign and malignant lesions of the breast and the performance of conventional univariate analysis.

Feature	Benign (n=55)	Malignant (n=159)	t/Z value	P value	Cut off	AUROC	Sensitivity (%)	Specificity (%)
Arterial phase NIC	0.033±0.036	0.110±0.068	−8.043	<0.001	0.052	0.86	83.0	76.4
Venous phase NIC	0.176±0.132	0.350±0.144	−7.900	<0.001	0.211	0.81	83.0	67.3
ΔNIC	0.143±0.120	0.240±0.109	−5.547	<0.001	0.178	0.74	71.7	69.0
Arterial phase λHu (HU/keV)	0.487±1.079	1.714±0.827	−8.701	<0.001	0.930	0.85	86.2	81.8
Venous phase λHu (HU/keV)	0.927±0.912	2.518±0.962	−10.717	<0.001	1.880	0.88	80.5	83.6
ΔλHu (HU/keV)	0.440±0.941	0.814±0.693	−3.129	0.002	−0.030	0.62	91.8	30.9
Arterial phase nZeff	0.684±0.032	0.725±0.042	−6.537	<0.001	0.720	0.79	61.0	92.7
Venous phase nZeff	0.824±0.035	0.868±0.052	−5.789	<0.001	0.840	0.79	81.1	67.9
ΔnZeff	0.140±0.032	0.143±0.054	−0.348	0.728	0.160	0.57	43.4	72.7
Precontrast phase attenuation (HU)	29.55±10.85	39.52±11.92	−5.465	<0.001	37.10	0.74	60.4	76.4
Arterial phase attenuation (HU)	31.70±13.24	54.56±15.55	−9.745	<0.001	42.40	0.87	83.6	81.8
Venous phase attenuation (HU)	38.28±16.00	65.64±18.28	−9.862	<0.001	54.00	0.87	77.4	83.6

The data is represented as means ± standard deviation. mpDECT, multiparametric dual-energy computed tomography; AUROC, area under the receiver operating characteristic curve; NIC, normalized iodine concentration; λ_Hu, slope of the spectral Hounsfield unit curve; nZ_eff, normalized effective atomic number; HU, Hounsfield unit.